{'fraction_non_alphanumeric': 0.022326674500587545, 'fraction_numerical': 0.005875440658049354, 'mean_word_length': 4.718120805369128, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of Imidazole on Glucose Tolerance and cAMP

Summary The in vivo effects of a phos-phodiesterase (PDE) stimulator, imidazole, and a PDE inhibitor, aminophylline, were studied in rats. Imidazole caused an impairment of OGTT but not IVGTT. Aminophylline caused a rise in cAMP levels of liver, muscle, and adipose tissue, whereas imidazole did not alter the cAMP levels in these tissues. It is concluded that the in vitro effect of imidazole is not manifest in vivo and the differing effects of the drug observed during the two routes of glucose administration can be explained better by interference with absorption of glucose through the GI tract rather than alteration of tissue cAMP levels. This study was supported in part by USPHS Grant No. AM16341. The authors are grateful to M. Ezekiel and S. Wilkins for their expert technical assistance.